Astria Scratches Dealmaking Itch, Paying Ichnos $15M to Join Eczema Race Led by Amgen, Sanofi

Ichnos Sciences has finally found a buyer for its OX40 eczema program. Astria Therapeutics has taken the other side of the deal, paying $15 million upfront to secure a spot at the back of a race led by Amgen and Sanofi.